Skip to content

Tolerance, Palatability and Acceptability Evaluation of an Oral Nutrition Supplement

Tolerance and Acceptability Evaluation of AYMES SWIFT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07452523
Enrollment
40
Registered
2026-03-05
Start date
2022-10-01
Completion date
2026-12-01
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease Related Malnutrition

Brief summary

To evaluate the tolerance (gastrointestinal) and acceptability of a new Oral Nutrition Supplement in patients with or at risk of disease related malnutrition.

Detailed description

To evaluate tolerance and acceptability of a new Oral Nutrition Supplement in patients with or at risk of malnutrition, who require supplementary nutrition support. Outcomes of GI effects, compliance and palatability will be recorded. To obtain data to support an ACBS submission (to allow for prescription in the community at NHS expense).

Interventions

DIETARY_SUPPLEMENTAYMES SWIFT oral nutritional supplement

The study supplement is an oral nutritional supplement and food for special medical purposes.

DIETARY_SUPPLEMENTAYMES SWIFT FIBRE

An oral nutritional supplement and food for special medical purposes.

DIETARY_SUPPLEMENTAYMES SWIFT PLANT

A plant based oral nutritional supplement and food for special medical purposes.

Sponsors

Aymes International Limited
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female •≥ 18 years of age * Identified as being malnourished/at risk of malnutrition-by-malnutrition screening tools \[i.e., MUST score ≥1, and/or using or requiring ONS at least once daily as part of nutritional management plan\] * Expected to receive at least one bottle of ONS per day * Written or electronic informed consent from patient, or verbally given consent countersigned by a witness for those physically unable to sign

Exclusion criteria

* Participants receiving parenteral nutrition or ≥70% total energy requirements from enteral tube feeding * Participants with major hepatic dysfunction (i.e., decompensated liver disease) * Participants with major renal dysfunction \[i.e., requiring filtration or stage 4/5 chronic kidney disease (CKD)\] * Participants with active/chronic gastrointestinal disease or impaired gastrointestinal function * Participants with significant dysphagia/high aspiration risk * Participation in other clinical intervention studies within 1 month of this study * Participants lacking mental capacity to consent * Allergy to any study product ingredients (appendix 2) * Investigator concern regarding ability or willingness of patient to comply with the study requirements.

Design outcomes

Primary

MeasureTime frameDescription
Acceptability and palatability of an oral nutriitonal supplement.7 daysTo assess the acceptability of the oral nutritional supplement in patients requiring oral nutritional supplementation. On day 7 of the intervention period an acceptability and preference questionnaire will be completed by the patient in order to seek their opinion on the taste, smell, texture and overall liking of the new oral nutrition supplement. Questions will be rated on a 7 point Likert scale (Strongly Agree, Somewhat agree, Neutral, Somewhat Disagree, Disagree, Disagree Strongly) and will relate to taste, smell, texure and overall liking.
Gastro-intestinal Tolerance7 daysTo assess the GI tolerance of the oral nutritional supplement in patients with or at risk of disease related malnutrition. Monitoring includes recording the number of any GI complaints and consistency of bowel movements via a diary for the first 7 days. A standardised gastrointestinal (GI) tolerance questionnaire to capture perceived severity (none, mild, moderate or severe) of common gastrointestinal symptoms (diarrhoea, constipation, bloating, abdominal discomfort, vomiting and nausea) will be recorded on day 1 (based on the 2 preceding days) and for the first 7 days during the intervention. Information about bowel movements will also be collected using the Bristol Stool Chart© at the same time points.
Compliance7 daysTo assess the compliance of patients taking the Study product as prescribed. This is measured by daily completion of a compliance diary, comparing consumed amount versus prescribed amount.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026